Belite Bio (FRA:D01) Total Stockholders Equity: €674.12 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:D01 Belite Bio Inc FRA:D01
19 GF Score
Price €130.00
! 3 Warning Signs
View Full Analysis

What is Belite Bio Total Stockholders Equity?

Belite Bio FRA:D01 -2.99% 19 Total Stockholders Equity is €674.12 Mil as of Jun. 2026. GuruFocus rates FRA:D01 with a GF Score™ of 19/100. The stock has 3 warning signs investors should review.

Belite Bio's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €674.12 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Belite Bio's Book Value per Share for the quarter that ended in Jun. 2026 was €16.74. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Belite Bio's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.00.

Belite Bio  (FRA:D01) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Belite Bio's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(674.12-0)/40.272
=16.74

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Belite Bio's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 674.12
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belite Bio Total Stockholders Equity Related Terms

Belite Bio Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Belite Bio's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belite Bio Total Stockholders Equity Chart

Belite Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial -13.36 39.18 82.93 139.26 658.00

Belite Bio Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 129.95 233.52 658.00 688.36 674.12
FRA:D01
19GF Score
Belite Bio Inc FRA:D01
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €674.12 Mil mean?
Belite Bio (FRA:D01) has a Total Stockholders Equity of €674.12 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Belite Bio and its competitors.
Is Belite Bio's Total Stockholders Equity too high?
Belite Bio's current Total Stockholders Equity is €674.12 Mil. Overall, Belite Bio has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Belite Bio's Total Stockholders Equity compare to ORKA and TVTX?
Belite Bio's Total Stockholders Equity of €674.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Belite Bio and its competitors. Belite Bio's current Total Stockholders Equity is €674.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belite Bio stock overvalued right now?
Belite Bio (FRA:D01) has a current Total Stockholders Equity of €674.12 Mil. The current Total Stockholders Equity is €674.12 Mil. Belite Bio's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Belite Bio (FRA:D01), the current Total Stockholders Equity is €674.12 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belite Bio Business Description

Other Exchanges BLTE:USAD01:Germany
Address 12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
19GF Score

Get the complete analysis for FRA:D01

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€130.00
Price